21 CFR 211.194(a)
Every DSRV article whose Regulatory Snapshot cites 21 CFR 211.194(a): the enforcement case behind it, the inspection exposure it created, and what the desk would do about it.
- What has FDA cited under 21 CFR 211.194(a)?
- 2 DSRV articles cite 21 CFR 211.194(a). Enforcement cases behind them: Genzyme Ireland FDA Warning Letter, June 22, 2026; FDA data integrity warning letters to Sun Pharmaceutical, Ipca Laboratories, and Hetero Drugs, read against FDA's guidance for industry, Data Integrity and Compliance With Drug CGMP: Questions and Answers, December 2018. Inspection exposure across them: 2 high.
- What does DSRV recommend for 21 CFR 211.194(a)?
- From the newest article (FDA Is Treating Discarded Evidence as a Quality Unit Failure): Inspection readiness is not having enough records after the fact — it is decision trails strong enough that FDA does not have to guess what the quality unit knew, reviewed, or allowed. DSRV is decision support, not legal advice; verify against the official source each article names.
- 7 min readHigh exposurecited as a tag
FDA Is Treating Discarded Evidence as a Quality Unit Failure
FDA's June 22, 2026 warning letter to Genzyme Ireland shows how undocumented retesting, discarded review artifacts, and canceled deviations now read as quality-unit governance failures. Small pharma quality teams should treat this as a warning that incomplete records are no longer a narrow documentation problem.
- Case
- Genzyme Ireland FDA Warning Letter, June 22, 2026
- DSRV take
- Inspection readiness is not having enough records after the fact — it is decision trails strong enough that FDA does not have to guess what the quality unit knew, reviewed, or allowed.
- 7 min readHigh exposurecited as a tag
FDA Data Integrity Enforcement Is Accelerating — Here's What the Warning Letters Actually Say
Data integrity citations appeared in over 60% of pharmaceutical manufacturing warning letters in 2025. FDA is citing the systems that allowed falsification to happen unchallenged — not just the falsification itself. Here is what the enforcement record shows and what separates sites that pass from those that don't.
- Case
- FDA data integrity warning letters to Sun Pharmaceutical, Ipca Laboratories, and Hetero Drugs, read against FDA's guidance for industry, Data Integrity and Compliance With Drug CGMP: Questions and Answers, December 2018.
- DSRV take
- The separating control is whether audit trail review, OOS-rate trending, and validated technical access controls run as scheduled operations, because FDA reads an undetected manipulation pattern as a failed quality system rather than an analyst problem.
Pressure-test your evidence before an inspector reads it
Bring the document that has to hold up under 21 CFR 211.194(a). DSRV maps the evidence, names the gaps, and routes judgment calls to human review. Controlled intake, no public file upload.
Regulatory intelligence and interpretation, not legal advice. Verify against the official FDA or ICH source each article names.